Baseline patient characteristics of the 2 largest retrospective studies using anti-PD-1 mAb’s after allo-HCT
| Characteristics . | All patients . | No GVHD . | Developed GVHD . |
|---|---|---|---|
| No. of patients | 51 | 28 | 23* |
| Average age | 36 | 36 | 37 |
| Disease | |||
| Hodgkin | 49 | 28 | 21 |
| Non-Hodgkin lymphoma | 2 | 0 | 2 |
| Donor type | |||
| Matched sibling | 27 | 13 | 14 |
| Matched unrelated | 14 | 7 | 7 |
| Mismatch unrelated | 2 | 2 | 0 |
| Haploidentical related | 5 | 4 | 1 |
| Umbilical cord blood | 3 | 2 | 1 |
| Peripheral blood graft source, n | 39 | 18 | 21 |
| RIC, n | 38 | 20 | 18 |
| Calcineurin inhibitor–based GVHD prophylaxis, n | 51 | 28 | 23 |
| Prior history of GVHD | |||
| aGVHD | 16 | 7 | 9 |
| cGVHD | 16 | 7 | 9 |
| No prior GVHD | 19 | 14 | 5 |
| Average time from allo-HCT to anti-PD-1 initiation (days) | 994 | 1210 | 731 |
| Receiving systemic immunosuppressive therapy at time of anti-PD-1, n | 8 | 5 | 3 |
| Characteristics . | All patients . | No GVHD . | Developed GVHD . |
|---|---|---|---|
| No. of patients | 51 | 28 | 23* |
| Average age | 36 | 36 | 37 |
| Disease | |||
| Hodgkin | 49 | 28 | 21 |
| Non-Hodgkin lymphoma | 2 | 0 | 2 |
| Donor type | |||
| Matched sibling | 27 | 13 | 14 |
| Matched unrelated | 14 | 7 | 7 |
| Mismatch unrelated | 2 | 2 | 0 |
| Haploidentical related | 5 | 4 | 1 |
| Umbilical cord blood | 3 | 2 | 1 |
| Peripheral blood graft source, n | 39 | 18 | 21 |
| RIC, n | 38 | 20 | 18 |
| Calcineurin inhibitor–based GVHD prophylaxis, n | 51 | 28 | 23 |
| Prior history of GVHD | |||
| aGVHD | 16 | 7 | 9 |
| cGVHD | 16 | 7 | 9 |
| No prior GVHD | 19 | 14 | 5 |
| Average time from allo-HCT to anti-PD-1 initiation (days) | 994 | 1210 | 731 |
| Receiving systemic immunosuppressive therapy at time of anti-PD-1, n | 8 | 5 | 3 |
Including 10 deaths related to GVHD.